High expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndrome

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2211-2218

  Gu, Shucheng ^a   Zhao, Youshan ^a   Guo, Juan ^a   Xu, Feng ^a   Fei, Chengming ^a   Zhang, Xi ^a   Xiao, Chao ^a   Chang, Chunkang ^a   Li, Xiao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

APAF 1; Erythroid apoptosis; esiRNAs; Iron overload; Myelodysplastic syndrome

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 9; DEFEROXAMINE; FERRIC AMMONIUM CITRATE; SMALL INTERFERING RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; COLORIMETRY; ENZYME ACTIVITY; ERYTHROID CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IRON OVERLOAD; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BLOTTING, WESTERN; CELL SEPARATION; ERYTHROCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; IRON OVERLOAD; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; YOUNG ADULT;

EID: 84898911698     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1294-x     Document Type: Article

References (24)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361(19):1872-85.
2. Malcovati L, Della Porta MG, Laarakkers CM, et al. Erythroid activity, transfusion iron overload, and hepcidin levels in patient with myelodysplastic syndrome. Blood, 2008; 112: abstract 2676.
3. Gattermann N, Rachmilewitz EA. Iron overload in MDS - pathophysiology, diagnosis, and complications. Ann Hematol. 2011;90(1):1-10.
4. Ambaglio I, Malcovati L, Papaemmanuil E, et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica. 2013;98(3):420-3.
5. Hershko C, Graham G, Bates GW, Rachmilewitz E. Nonspecific serum iron in thalassemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40(2):255-63.
6. Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. Int J Hematol. 2003;77(4):342-50.
7. Tehranchi R, Fadeel B, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood. 2003;101(3):1080-6.
8. Hellstrom-Lindberg E, Schmidt-Mende J, Forsblom AM, Christensson B, Fadeel B, Zhivotovsky B. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol. 2001;112(3):714-26.
9. Brunning R, Orazi A, Germing U, et al. Myelodysplastic syndromes. In: Swerdlow S, Campo E, Harris NL, et al., eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissue, 4th ed. Lyon: IARC Press. 2008: 88-103.
10. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-88.
11. Greenberg P, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.
12. Armand P, Kim H, Rhodes J, et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(6):852-60.
13. Matsuoka A, Tochigi A, Kishimoto M, et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia. 2010;24(4):748-55.
14. Lindberg EH. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes. Curr Drug Targets. 2005;6(6):713-25.
15. Jia L, Srinivasula S, Liu F, et al. Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood. 2001;98(2):414-21.
16. Fu WN, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, et al. Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene. 2005;22:451-5.
17. Sturm I, Bosanquet AG, Radetzki S, Hummel M, Dörken B, et al. Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation. Int J Cancer. 2006;118:2329-36.
18. Sun Y, Orrenius S, Pervaiz S, Fadeel B. Plasma membrane sequestration of apoptotic protease-activating factor-1 in human B-lymphoma cells: a novel mechanism of chemoresistance. Blood. 2005;105:4070-7.
19. Zermati Y, Mouhamad S, Stergiou L, et al. Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol Cell. 2007;28(4):624-37.
20. Fadeel B, Ottosson A, Pervaiz S. Big wheel keeps on turning: apoptosome regulation and its role in chemoresistance. Cell Death Differ. 2008;15(3):443-52.
21. Benites B, Traina F, Santos Duarte A, et al. Increased expression of APAF-1 in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia. Eur J Haematol. 2011;84(6):525-30.
22. Cortelezzi A, Cattaneo C, Cristiani S, et al. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J. 2000;1(3):153-8.
23. Claessens YE, Bouscary D, Dupont JM, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood. 2002;99(5):1594-601.
24. Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol. 2010;17(3):184-90.